Navigation Links
Quark Pharmaceuticals Announces Poster Presentations at RNAi Europe 2008
Date:9/17/2008

es raises the necessity to target more than one gene at a time. At the same time, simultaneous delivery of different siRNAs targeting one and the same gene can increase the treatment specificity and reduce off-target effects.

Dr. Daniel Zurr, Quark's Chief Executive Officer, stated, "These poster presentations highlight our ongoing work to establish Quark's leadership in the field of RNAi by developing novel IP and expertise covering technology platforms that facilitate development of siRNA therapeutics. With the industry's most robust portfolio of siRNA therapeutics currently under evaluation in human clinical trials, Quark has proven its ability to advance siRNA products from discovery to the clinic."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry that the Company believes provide Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to organs including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In addition, Quark's current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery and DGFi with open IND for prevention of delayed graft function in kidney transplantation. Based on publicly available information, Quark believes AKIi-5 was the first siRNA delivered systemically in a human clinical trial.

In additio
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
2. Quark Pharmaceuticals to Participate in 9th Annual Beyond Genome Conference
3. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
4. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
5. Trubion Pharmaceuticals Wins Patent Opposition - Genentech / Biogen Idec European Patent Revoked
6. Dr. Paul Korner Joins Ferring Pharmaceuticals as Vice President, Medical Affairs
7. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
8. VIA Pharmaceuticals to Host Investor Science Briefing on the Role of Inflammation in Cardiovascular Disease on Tuesday, September 16
9. Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
10. Oramed Pharmaceuticals Partners With ETI Karle Clinical to Conduct Phase 2B Trials on Its Oral Insulin Capsule, ORMD 0801
11. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ... $1.4 million bringing Q3 orders to date to $5 million. ... North America . "We continue to see ... and CEO. "With these orders, our backlog has climbed to ... BIOREM is a leading clean technology company that designs, ...
(Date:9/23/2014)... Cambridge Semantics, the leading provider of Smart Data ... the recent ‘Hype Cycle for Life Sciences 2014 ’ ... key insights pertaining to the benefits in the knowledge ... Shanler and Stephen Davies, “The use of these systems ... scientific stakeholders, and support collaboration and innovation strategies as ...
(Date:9/23/2014)... September 23, 2014 Dr. Williams says, ... book on healthcare offers a three phase process that ... healthcare delivery system that would go far beyond anything ... regarding the delivery of healthcare.” , “Every effort to ... failed to provide discernable progress throughout that system because ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
Breaking Biology Technology:Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2
... , , ... ("China Pharma") (NYSE Amex: CPHI ), which develops,manufactures, and ... present at the Brean Murray, Carret & Co. 2009 China,Growth ... Broadway,hotel in New York. Management is scheduled to present ...
... , CRACKS AMAZON.COM BEST SELLER LIST IN SCIENCE ... top ten best selling science books , SEATTLE, Nov. 17 ... new book about the controversial theory of intelligent design made Amazon.com,s ... as the world marks 150 years since Charles Darwin published his ...
... , KVISTGARD, ... today that BARDA (Biomedical Advanced Research and,Development Authority) has ... of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine,with ... The contract provides funds to ...
Cached Biology Technology:China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference 2Intelligent Design Book Delivers Blow to Darwin 2US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine 2US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine 3
(Date:9/23/2014)... Ill. Antarctic fishes that manufacture their own ... Ocean also suffer an unfortunate side effect, researchers ... their bodies resist melting even when temperatures warm. ... Proceedings of the National Academy of Sciences ... an undesirable consequence of the evolution of antifreeze ...
(Date:9/23/2014)... man has domesticated animals, selecting the best traits ... offer an intriguing animal to examine adaptation to ... of selected breeding and a wealth of livestock ... kind study that combined molecular and environmental data, ... for genes under environmental selection from domesticated sheep ...
(Date:9/23/2014)... an athlete,s moving body relies on an orchestrated response of ... intersecting planes literally the geometry of a critical ... more than just a footfall error at the root of ... or anterior cruciate ligament tear. In fact, size of ... knee joint and volume of the ACL combine to ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezing ... and melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezing ... and melting 3Being sheepish about climate adaptation 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 2Does size matter? MRI imaging sheds light on athletes most at risk for severe knee injury 3
... is allowing scientists to better understand the movement of cells ... microenvironment. In a recent article published in Disease Models ... colleagues used optimized methods of laser microscopy to track the ... cancer. As a tumor grows, it triggers ...
... Activity in Identity ... Management and Biometrics, FALLS CHURCH, Va., Sept. ... relocating the CSC Identity Labs headquarters from Camp,Hill, Pa., to Fairmont, ... alignment with the federal government,s presence in the,I-79 High Technology Corridor, ...
... FL (September 16, 2008)- A team of scientists headed by neuroscientist ... grant by the National Institute of Health (NIH), to develop a ... injury. Dr. Chiba, a professor at the University of Miami,s Department ... groundbreaking process to enhance synapse formation or nerve regeneration., ...
Cached Biology News:CSC Identity Labs Headquarters Relocates to West Virginia 2CSC Identity Labs Headquarters Relocates to West Virginia 3NIH EUREKA grant awarded to University of Miami scientist 2
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
APO(a) EIA Sample Size: 25 l...
Biology Products: